6709.Two

The company's capital structure is characterized by a high level of equity, with total equity amounting to TWD 152,252,000, and a relatively low level of debt, with long-term debt at TWD 3,967,000. The liquidity position is reflected in a current ratio of 13.69, indicating strong short-term liquidity. However, the company has a negative operating cash flow of TWD -63,330,000 and a free cash flow of TWD -68,405,000, suggesting challenges in generating positive cash from operations.

Profitability metrics show a return on equity of -0.4485 and a return on assets of -0.4101, both significantly below zero, indicating that the company is not generating returns on its equity or assets. These figures are likely below the industry median for a company in the biotechnology and medical research sector, which typically requires high R&D investment and has long development cycles.

The company's revenue is reported as TWD 0.0, which suggests either a reporting anomaly or a period of no revenue generation. There is no detailed breakdown of segments or geographic exposure provided in the available data, making it difficult to assess revenue concentration or diversification.

The company's growth trajectory is unclear due to the absence of revenue history and outlook data. The lack of revenue and the negative operating and net income figures indicate a challenging financial position. The company is not currently generating revenue and is experiencing significant losses.

The risk assessment indicates a medium level of liquidity risk, with a low probability of dilution. The key flag of negative net cash after subtracting total debt highlights the company's liquidity challenges. The dilution potential is low, and no adjustments have been applied to the valuation metrics.

Recent events and filings are not detailed in the provided data, so there is no information on specific recent developments or transcripts that could provide insight into the company's strategic direction or operational changes.